NEW YORK and LONDON, August 18, 2015 Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered …
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Agreement to Create Orphan Disease Company Focused on Complement C5 Inhibition
NEW YORK and LONDON, July 13, 2015 Celsus Therapeutics (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a …
Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint
MRX-6 Cream Did Not Demonstrate Separation from Vehicle in Primary Endpoint of Percent Improvement in the Investigator's Global Assessment NEW YORK and …
Celsus Therapeutics Completes Enrollment of Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis
NEW YORK and LONDON, January 13, 2015 Topline data from double-blind portion of trial expected by end of February, 2015 Celsus Therapeutics (NASDAQ: …
Celsus Therapeutics Announces FDA Allowance of IND for Clinical Development of MRX-6 Cream in Atopic Dermatitis
NEW YORK and LONDON, January 12, 2015 Phase II dose ranging clinical trial in atopic dermatitis expected to begin in first quarter of 2015 Celsus …
